The p53 isoform Δp53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity

Cancer Research

Volumn 67, Issue 5, 2007, Pages 1959-1969

  Wan, Mui Chan ^a   Poon, Randy Y C ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; ISOPROTEIN; PROTEIN MDM2; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MDM2 PROTEIN, HUMAN; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA BINDING; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; UBIQUITINATION; ACTIVE TRANSPORT; CELL CULTURE; CELL NUCLEUS; CYTOPLASM; METABOLISM; NUCLEAR LOCALIZATION SIGNAL; PHYSIOLOGY; PROTEIN BINDING; PROTEIN PROCESSING; TRANSACTIVATION;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; HUMANS; NUCLEAR LOCALIZATION SIGNALS; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 33947254018     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3602     Document Type: Article

References (46)

1. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313-20.
2. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
4. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995;267:1498-502.
5. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.
6. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
7. Vogelstein B, Kinzler KW. Tumour-suppressor genes. X-rays strike p53 again. Nature 1994;370:174-5.
8. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13:1027-36.
9. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003;15:164-71.
10. Badciong JC, Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002;277:49668-75.
11. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-91.
12. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
13. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71-7.
14. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000;14:278-88.
15. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000;287:1824-7.
16. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
17. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006;13:962-72.
18. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
19. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003;21:182-91.
20. Flaman JM, Waridel F, Estreicher A, et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996;12:813-8.
21. Chow VT, Quek HH, Tock EP. Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line. Cancer Lett 1993;73:141-8.
22. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 2002;4:462-7.
23. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004;24:7987-97.
24. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-37.
25. Rohaly G, Chemnitz J, Dehde S, et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005;122:21-32.
26. Chan WM, Siu WY, Lau A, Poon RYC. How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 2004;24:3536-51.
27. Wang XQ, Ongkeko WM, Lau AW, Leung KM, Poon RYC. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res 2001;61:1598-603.
28. Leung KM, Po LS, Tsang FC, et al. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res 2002;62:4890-3.
29. Yam CH, Siu WY, Lau A, Poon RYC. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J Biol Chem 2000;275:3158-67.
30. Wang X, Arooz T, Siu WY, et al. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 2001;490:202-8.
31. 2-M by mechanisms fundamentally different from other cyclins. J Biol Chem 2002;277:35140-9.
32. Yam CH, Ng RW, Siu WY, Lau AW, Poon RYC. Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol Cell Biol 1999;19:635-45.
33. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
34. Ausubel F, Brent R, Kingston R, et al. Current protocols in molecular biology. New York John Wiley & Sons; 1991.
35. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992;89:5547-51.
36. Poon RYC, Toyoshima H, Hunter T. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995;6:1197-213.
37. Yam CH, Siu WY, Arooz T, et al. MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res 1999;59:5075-8.
38. Ho CC, Siu WY, Lau A, Chan WM, Arooz T, Poon RYC. Stalled replication induces p53 accumulation through distinct mechanisms from DNA damage checkpoint pathways. Cancer Res 2006;66:2233-41.
39. 2 arrest in response to overexpression of p53. Mol Biol Cell 1999;10:3607-22.
40. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10:6565-77.
41. Chan WM, Mak MC, Fung TK, Lau A, Siu WY, Poon RYC. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res 2006;4:15-25.
42. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003;302:1972-5.
43. Gu J, Kawai H, Wiederschain D, Yuan ZM. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Res 2001;61:1741-6.
44. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001;21:8521-32.
45. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847-62.
46. Diehl JA, Sherr CJ. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 1997;17:7362-74.